Full Press Release Details
1 Name and Address of Company
Zentaris Inc. (the "Company")
Stikeman Elliott LLP
2 Date of Material Change
October 4, 2019, the Company issued a news release indicating the material change, which was disseminated on the GlobeNewswire
4 Summary of Material Change
October 4, 2019, the Company announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company,
effective October 4, 2019, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company.
5.1 Full Description of Material Change
October 4, 2019, the Company announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company,
effective October 4, 2019, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company.
Paulini will continue to be based in Frankfurt, Germany, and his appointment as President and Chief Executive Officer aligns with
the Company's refocus on its operations in Germany. The Company's registered office will remain in Toronto, Ontario,
Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role in the spinoff and formation
of Aeterna Zentaris GmbH from ASTA Medica. Dr. Paulini has managed many of the Company's clinical development projects including
research and development of Macrilen (macimorelin). Dr. Paulini obtained his PhD (Dr. Ing.) in chemistry at the Technical
University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry and drug discovery during subsequent postdoctoral
fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany).
5.2 Disclosure for Restructuring Transactions
6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
7 Omitted Information
information regarding the matters described in this report may be obtained from Leslie Auld, Chief Financial Officer, at 843-900-3201